BLFS insider buying and SEC filings, explained
Biolife Solutions Inc. · CIK 834365
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$33.7M
Planned sales (10b5-1)
$301K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 19–21, 2026 | Sale | Eli Casdin (10% owner) sold 1,200,000 shares indirectly between May 19 and May 21 at about $23.44 ($28.1M). Indirect holdings down 20% to 4,757,165 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed May 21, 2026 |
| Mar 23, 2026 | Planned (10b5-1) | Karen A. Foster (Chief Quality and Operations) sold 2,577 shares at about $19.17 ($49K), marked as a 10b5-1 plan trade. Holdings down 2% to 108,758 shares. | SEC filing Filed Mar 31, 2026 |
| Mar 5–9, 2026 | Sale | Karen A. Foster (Chief Quality and Operations) sold 97,423 shares between Mar 5 and Mar 9 at about $20.15 ($2.0M). Holdings down 46% to 113,242 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 9, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Sean Werner (Chief Technology Officer) sold 111 shares at $20.74 ($2K), marked as a 10b5-1 plan trade. Holdings down <1% to 49,932 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Karen A. Foster (Chief Quality and Operations) sold 418 shares at $20.74 ($9K), marked as a 10b5-1 plan trade. Holdings down <1% to 210,665 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Aby J. Mathew (EVP & Chief Scientific Officer) sold 529 shares at $20.74 ($11K), marked as a 10b5-1 plan trade. Holdings down <1% to 392,937 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Troy Wichterman (CFO) sold 588 shares at $20.74 ($12K), marked as a 10b5-1 plan trade. Holdings down <1% to 220,649 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Sarah Aebersold (Chief Human Resources Officer) sold 219 shares at $20.74 ($5K), marked as a 10b5-1 plan trade. Holdings down <1% to 93,360 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Todd Berard (Chief Marketing Officer) sold 353 shares at $20.74 ($7K), marked as a 10b5-1 plan trade. Holdings down <1% to 165,940 shares. | SEC filing Filed Mar 5, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Troy Wichterman (CFO) sold 990 shares at $25.59 ($25K), marked as a 10b5-1 plan trade. Holdings down 1% to 150,746 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Karen A. Foster (Chief Quality and Operations) sold 335 shares at $25.59 ($9K), marked as a 10b5-1 plan trade. Holdings down <1% to 191,984 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Sarah Aebersold (Chief Human Resources Officer) sold 241 shares at $25.59 ($6K), marked as a 10b5-1 plan trade. Holdings down <1% to 75,765 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Aby J. Mathew (EVP & Chief Scientific Officer) sold 405 shares at $25.59 ($10K), marked as a 10b5-1 plan trade. Holdings down <1% to 349,350 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Todd Berard (Chief Marketing Officer) sold 344 shares at $25.59 ($9K), marked as a 10b5-1 plan trade. Holdings down <1% to 132,564 shares. | SEC filing Filed Jan 8, 2026 |
| Dec 15, 2025 | Sale | Amy DuRoss (Director) sold 2,000 shares at $24.60 ($49K). Holdings down 10% to 18,687 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 17, 2025 |
| Dec 9, 2025 | Planned (10b5-1) | Aby J. Mathew (EVP & Chief Scientific Officer) sold 631 shares at $25.13 ($16K), marked as a 10b5-1 plan trade. Holdings down <1% to 349,755 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 9, 2025 | Planned (10b5-1) | Troy Wichterman (CFO) sold 1,033 shares at $25.13 ($26K), marked as a 10b5-1 plan trade. Holdings down 1% to 151,736 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 9–15, 2025 | Planned (10b5-1) | Sarah Aebersold (Chief Human Resources Officer) sold 946 shares between Dec 9, 2025 and Dec 15, 2025 at about $24.63 ($23K), marked as a 10b5-1 plan trade. Holdings down 1% to 76,006 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 9, 2025 | Planned (10b5-1) | Todd Berard (Chief Marketing Officer) sold 358 shares at $25.13 ($9K), marked as a 10b5-1 plan trade. Holdings down <1% to 132,908 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 9, 2025 | Planned (10b5-1) | Karen A. Foster (Chief Quality and Operations) sold 519 shares at $25.13 ($13K), marked as a 10b5-1 plan trade. Holdings down <1% to 192,319 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 4, 2025 | Sale | Troy Wichterman (CFO) sold 30,000 shares at about $25.72 ($772K). Holdings down 16% to 152,769 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 5, 2025 |
| Nov 25–26, 2025 | Sale | Amy DuRoss (Director) sold 4,000 shares between Nov 25, 2025 and Nov 26, 2025 at $27.00 ($108K). Holdings down 16% to 20,687 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 28, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Todd Berard (Chief Marketing Officer) sold 351 shares at $26.74 ($9K), marked as a 10b5-1 plan trade. Holdings down <1% to 133,266 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Troy Wichterman (CFO) sold 584 shares at $26.74 ($16K), marked as a 10b5-1 plan trade. Holdings down <1% to 182,769 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Sarah Aebersold (Chief Human Resources Officer) sold 217 shares at $26.74 ($6K), marked as a 10b5-1 plan trade. Holdings down <1% to 76,952 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Karen A. Foster (Chief Quality and Operations) sold 415 shares at $26.74 ($11K), marked as a 10b5-1 plan trade. Holdings down <1% to 192,838 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Sean Werner (Chief Technology Officer) sold 110 shares at $26.74 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 25,927 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Aby J. Mathew (EVP & Chief Scientific Officer) sold 526 shares at $26.74 ($14K), marked as a 10b5-1 plan trade. Holdings down <1% to 350,386 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 19–21, 2025 | Sale | Amy DuRoss (Director) sold 6,000 shares between Nov 19, 2025 and Nov 21, 2025 at about $24.76 ($149K). Holdings down 20% to 24,687 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 21, 2025 |
| Nov 11–13, 2025 | Sale | Greef Roderick De (CEO and Director) sold 100,000 shares between Nov 11, 2025 and Nov 13, 2025 at about $25.80 ($2.6M). Holdings down 20% to 389,998 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 13, 2025 |
54 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow BLFS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.